stockportfolio.pro
CYTK vs OSCR: Which Stock Is the Better Buy?
Cytokinetics, Incorporated and Oscar Health, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — CYTK vs OSCR, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Cytokinetics, Incorporated (CYTK) | Oscar Health, Inc. (OSCR) | |
|---|---|---|
| Market cap | $9.1B | $8.5B |
| Revenue (latest FY) | $88.04M | $11.70B |
| Net income (latest FY) | $-784.96M | $-443.15M |
| Revenue growth (5y CAGR) | 9.5% | 90.8% |
| Net margin | -891.6% | -3.8% |
| Return on equity | 119.0% | -45.3% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 1 |
| Positive free cash flow | No | Yes |
See the full CYTK vs OSCR breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open CYTK's full financials → Open OSCR's full financials →More comparisons
Frequently asked questions
Which is bigger, CYTK or OSCR?
Cytokinetics, Incorporated is larger by market capitalization — $9.1B versus $8.5B.
Which grows faster, CYTK or OSCR?
Over the last five fiscal years, Oscar Health, Inc. grew revenue faster — 90.8%/yr versus 9.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.